Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02608697 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia
A Phase 2 study, sponsored by Catabasis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 153
- Enrollment target
NCT02608697 is a Phase 2 study that has completed, run by Catabasis Pharmaceuticals. The registered enrollment target is 153 participants.
The verdict
NCT02608697, a Phase 2 study, has completed, sponsored by Catabasis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 153 participants
- Enrollment target
Study Summary
The purpose of this placebo-controlled, double-blind study is to assess the effect of several doses of CAT-2054 on LDL-C in hypercholesterolemic patients on a stable dose of high-intensity statin, and to evaluate the safety and tolerability of different doses of CAT-2054 for 4 weeks.
Interventions
- DRUG Placebo
- DRUG Atorvastatin
- DRUG CAT-2054
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2015-10 |
| Est. Completion | 2016-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02608697
The ClinicalTrials.gov registry entry for NCT02608697 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 153 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Catabasis Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02608697 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02608697 about?
NCT02608697 is a clinical study titled "A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia". The purpose of this placebo-controlled, double-blind study is to assess the effect of several doses of CAT-2054 on LDL-C in hypercholesterolemic patients on a stable dose of high-intensity statin, and to evaluate the safety and tolerability of different doses of CAT-2054 for 4 weeks.
What is the current status of trial NCT02608697?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 153 participants. The study started on 2015-10. Estimated completion is 2016-06.
What interventions are being tested in trial NCT02608697?
The interventions under investigation include: Placebo (DRUG), Atorvastatin (DRUG), CAT-2054 (DRUG).
Who is sponsoring clinical trial NCT02608697?
This trial is sponsored by Catabasis Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.